Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

Schreiber, Stefan; Hämling, J; Zehnter, E; Howaldt, Stefanie; Daerr, W; Raedler, Andreas; Kruis, Wolfgang

doi:10.1136/gut.40.6.761

Cited by 93 publications

(72 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, some authors have concluded that an increased prevalence of tubular proteinuria may be attributed to high doses of 5-ASA. 15 Nevertheless, differences between results reported in these studies may relate to differences in disease activity of IBD. In this respect, microalbuminuria values have been shown to fall when the disease is quiescent, 9,10 even though the patients were receiving 5-ASA treatment.…”

Section: Proteinuria In Patients With Ibdmentioning

confidence: 95%

5-Aminosalicylates and renal function in inflammatory bowel disease

Gisbert

González-Lama

Maté

2007

Inflammatory Bowel Diseases

201

144

View full text Add to dashboard Cite

Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured regularly show that nephrotoxicity is exceptional (mean rate of only 0.26% per patient-year). There have been several case reports, including 46 patients, of renal disease associated with 5-ASA treatment in patients with IBD. 5-ASA treatment-related nephrotoxicity is reported most often within the first 12 months, but also delayed presentation after several years has been shown. The absence of a clear relationship between 5-ASA dose and the risk of nephrotoxicity suggests that this complication is idiosyncratic rather than dose-related. Most of the patients with renal disease associated with 5-ASA treatment suffered interstitial nephritis, with symptoms and signs being nonspecific, which may delay detection for many months. The nephrotoxicity potential of mesalazine and sulfasalazine seems to be similar. The risk with different oral preparations of 5-ASA is probably too small to influence the choice of agent. Mesalazine should be withdrawn when renal impairment manifests in a patient with IBD; if this does not result in a fall in serum creatinine, then renal biopsy should be considered. A trial of high-dose steroid may be recommended in patients whose renal function does not respond to drug withdrawal. The optimal monitoring schedule of serum creatinine in patients receiving 5-ASA treatment remains to be established, as there is no evidence to date that either the test, or the frequency of testing, improves patient outcomes.

show abstract

Section: Proteinuria In Patients With Ibdmentioning

confidence: 95%

5-Aminosalicylates and renal function in inflammatory bowel disease

Gisbert

González-Lama

Maté

2007

Inflammatory Bowel Diseases

201

144

View full text Add to dashboard Cite

show abstract

“…ALP is phosphohydrolase enzyme, attached with glycosyl phosphatidyl inositol, anchors to the cell wall and its activity is considered as an important hallmark for inflammation during the UC (Schreiber et al 1997). The elevated levels of ALP support the inflammatory changes in UC.…”

Section: Discussionmentioning

confidence: 99%

Beneficial effect of Amorphophallus paeoniifolius tuber on experimental ulcerative colitis in rats

Dey

Sharma

Wanjari

et al. 2016

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: The tuber of Amorphophallus paeoniifolius (Dennst.) Nicolson (Araceae), commonly called Suran or Jimmikand, has high medicinal value and is used ethnomedicinally for the treatment of different gastrointestinal and inflammatory disorders. Objective: The present study evaluated the effects of extracts of Amorphophallus paeoniifolius tubers on acetic acid-induced ulcerative colitis (UC) in rats. Materials and methods: Wistar rats were orally administered methanol extract (APME) or aqueous extract (APAE) (250 and 500 mg/kg) or standard drug, prednisolone (PRDS) (4 mg/kg) for 7 days. On 6th day of treatment, UC was induced by transrectal instillation of 4% acetic acid (AA) and after 48 h colitis was assessed by measuring colitis parameters, biochemical estimations and histology of colon. Results: APME or APAE pretreatment significantly (p < .05-.001) prevented AA-induced reduction in body weight and increase in colitis parameters viz. stool consistency, colon weight/length ratio and ulcer score, area and index. Extracts treatment attenuated (p < .001) increase in alkaline phosphatase and lactate dehydrogenase in serum and myeloperoxidase activity and cytokines in colon tissue due to AA administration. Extracts treatment prevented AA-induced elevation in lipid peroxidation and decline in activities of superoxide dismutase and catalase and reduced-glutathione content (p < .05-.001) along with histopathological alterations. PRDS also showed similar ameliorative effect on colitis. Discussion and conclusion: APME and APAE showed a preventive effect on UC, and ameliorated inflammation and oxidative damage in colon. The effects may be attributed to presence of phytochemicals, betulinic acid, b-sitosterol, and glucomannan. In conclusion, the tuber of Amorphophallus paeoniifolius exhibited an anticolitic effect through anti-inflammatory and antioxidant action. ARTICLE HISTORY

show abstract

“…An area that has yet to be addressed relates to the influence of IBD medications on protein abundance levels. Schreiber et al [47] reported the possible link between high dose 5aminosalicylic acid (5ASA) and modulated urinary protein concentrations. However, other groups have suggested that these urinary pro teins reflect renal extraintestinal manifestations rather than 5ASA toxicity [48,49] .…”

Section: Fecal Calprotectinmentioning

confidence: 99%

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Chan¹,

Wasinger²,

Leong³

2016

WJGP

View full text Add to dashboard Cite

Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease (IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD.

show abstract

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

Abstract: Background-An increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid.

Cited by 93 publications

References 31 publications

5-Aminosalicylates and renal function in inflammatory bowel disease

5-Aminosalicylates and renal function in inflammatory bowel disease

Beneficial effect of Amorphophallus paeoniifolius tuber on experimental ulcerative colitis in rats

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Contact Info

Product

Resources

About